Lipoprotein associated phospholipase A2: role in atherosclerosis and utility as a biomarker for cardiovascular risk

Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease

(2010) Ida J Hatoum et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

(2010)   LANCET

Darapladib and atherosclerotic plaque: Should lipoprotein-associated phospholipase A2 be a therapeutic target?

(2009) Peter A. McCullough   Current Atherosclerosis Reports

Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community

(2009) Olle Melander   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effects of lifestyle counseling and combination lipid-modifying therapy on lipoprotein-associated phospholipase A2 mass concentration

(2009) Kota J. Reddy et al.   Journal of Clinical Lipidology

Relationship of lipoprotein-associated phospholipase A2and oxidized low density lipoprotein in carotid atherosclerosis

(2009) Kasey C. Vickers et al.   JOURNAL OF LIPID RESEARCH

Fenofibrate reduces lipoprotein associated phospholipase A 2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome

(2008) Robert S. Rosenson   AMERICAN HEART JOURNAL

Consensus Panel Recommendation for Incorporating Lipoprotein-Associated Phospholipase A2 Testing into Cardiovascular Disease Risk Assessment Guidelines

(2008) Michael H. Davidson et al.   AMERICAN JOURNAL OF CARDIOLOGY

Review of the Evidence for the Clinical Utility of Lipoprotein-Associated Phospholipase A2 as a Cardiovascular Risk Marker

(2008) Marshall A. Corson et al.   AMERICAN JOURNAL OF CARDIOLOGY

Effects of the Direct Lipoprotein-Associated Phospholipase A 2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque

(2008) Patrick W. Serruys et al.   CIRCULATION

Lipoprotein-Associated Phospholipase A 2 , Hormone Use, and the Risk of Ischemic Stroke in Postmenopausal Women

(2008) Sylvia Wassertheil-Smoller et al.   HYPERTENSION

The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent

(2008) Emile R. Mohler et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development

(2008) Robert L Wilensky et al.   NATURE MEDICINE

Enhanced Expression of Lp-PLA 2 and Lysophosphatidylcholine in Symptomatic Carotid Atherosclerotic Plaques

(2008) Dallit Mannheim et al.   STROKE

Lipoprotein-Associated Phospholipase A 2 and High-Sensitivity C-Reactive Protein Improve the Stratification of Ischemic Stroke Risk in the Atherosclerosis Risk in Communities (ARIC) Study

(2008) Vijay Nambi et al.   STROKE